Effect of ezetimibe-simvastatine over endothelial dysfunction in dyslipidemic patients: Assessment by 13N-ammonia positron emission tomography

Journal of Nuclear Cardiology

Volumn 17, Issue 6, 2010, Pages 1015-1022

  Alexanderson, Erick ^a   García Rojas, Leonardo ^a   Jiménez, Moisés ^b   Jácome, Rodrigo ^a   Calleja, Rodrigo ^a   Martínez, Alfonso ^a   Ochoa, Juan M ^a   Meave, Aloha ^a,b   Alexanderson, Graciela ^c  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

13N ammonia PET; Coronary artery disease; Endothelial dysfunction; Imaging; PET

Indexed keywords

ADENOSINE; AMMONIA N 13; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD VESSEL REACTIVITY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COLD PRESSOR TEST; CONTROLLED STUDY; CORONARY FLOW RESERVE; DRUG EFFECT; DRUG RESPONSE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART MUSCLE BLOOD FLOW; HUMAN; HYPEREMIA; MALE; PATIENT ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADENOSINE; ADOLESCENT; ADULT; AGED; AMMONIA; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CASE-CONTROL STUDIES; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NITROGEN ISOTOPES; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RISK FACTORS; SIMVASTATIN;

EID: 78651302583     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12350-010-9273-8     Document Type: Article

References (34)

1. Goff DC, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, et al. Dyslipidemia prevalence, treatment, and control in the multi-ethnic study of atherosclerosis (MESA). Circulation 2006;113:647-56.
2. Kannel WB. The Framingham study: ITS 50-year legacy and future promise. J Atheroscler Thromb 2000;6(2):60-6.
3. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837.
4. Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screeners of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8.
5. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-72.
6. De Silva R, Camici PG. The role of positron emission tomography in the investigation of coronary circulatory function in man. Cardiovasc Res 1994;28:1595-612.
7. Nitzche EU, Choi Y, Czernin J, Hoh C, Huang SU, Schelbert H. Noninvasive quantification of myocardial blood flow in Humans. A direct comparison of the [13 N]ammonia and the [15O]water techniques. Circulation 1996;93:2000-6.
8. Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991;84:1984-92.
9. Alexanderson E, Romero J, Ricalde A, Alexanderson G, Meave A. Assessment of endothelial function by positron emission tomography. Curr Cardiol Rev 2006;2:2.
10. Schelbert H, Wisenberg G, Phelps ME, Gould KL, Henze E, Hoffman EJ, Gomes A, Kuhl DE. Noninasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilation, VI: Detection of coronary artery disease in man with intravenous 13-NH3 and positron computed tomography. Am J Cardiol 1982;49:1197-207.
11. Kaufmann P, Gnecchi-Ruscone T, et al. Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia. J Am Coll Cardiol 2000;36:103-9.
12. Raitakari OT, Pitkanen O-P, Lehtimaki T, Lahdenpera S, Iida H, Yla-Herttuala S, Luoma J, Mattila K, Nikkari T, Taskinen M-L, Viikari JSA, Knuuti J. In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. J Am Coll Cardiol 1997;30:97-102.
13. Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R, Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterollowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999;99:2871-5.
14. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid lowering therapy and achieving low density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459M67.
15. Knopp RH, Gitter H, Truitt T, for the Ezetimibe Study Group, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-41.
16. DavidsonMH,McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34.
17. Gagne C, Bays HE, Weiss SR, for the Ezetimibe Study Group, et al. Efficacy and safety of ezetimibe added to ongoing stain therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91.
18. Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
19. Wienhard K, Dahlbom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U, Heiss WD. The ECAT EXACT HR: Performance of a new high resolution positron scanner. J Comput Assist Tomogr 1994;18:110-8.
20. Kuhle WG, Porenta G, Huang SC, Buxton D, Gambhir SS, Hansen H, Phelps ME, Schelbert HR. Quantification of regional myocardial blood flow using [13N]ammonia and reoriented dynamic positron emission tomographic imaging. Circulation 1992;86:1004-17.
21. Campisi R, Di Carli Marcelo. Assessment of coronary flow reserve and microcirculation: A clinical perspective. J Nucl Cardiol 2004;11:3-11.
22. Alexánderson E, Ricalde A, Estradas J, Alexánderson EG, Meave A. Evaluation of coronary blood flow by means of PET in the Mexican population without coronary artery disease. Arch Cardiol Mex 2005;75:35-41.
23. Hein WH, Kuo L. LDLs impair vasomotor function of the coronary microcirculation: role of superoxide anions. Circ Res 1998;83:404-14.
24. Anderson TJ, Meredith IT, Charbonneau F, et al. Endotheliumdependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996;93:1647-50.
25. Yokoyama I, Ohtake T, Momamura S-I, et al. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation 1996;94:3232-8.
26. Dayanikli F, Grambow D, Muzik O, Mosca L, Rubenfire, Schwaiger M. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation 1994;90:808-17.
27. Schindler TH, Nitzche EU, Schelbert HR, Olschewski M, Sayre J, Mix M, et al. Positron emission tomography-measured abnormal responses of myocardial blood flow to sympathetic stimulation are associated with the risk of developing cardiovascular events. J Am Coll Cardiol 2005;45:1505-12.
28. Alexanderson E, Garcia-Rojas L, Rodriguez M, et al. Endothelial function assessment by positron emission tomography in patients with hypercholesterolemia. Arch Cardiol Mex 2008;78(2):139-47.
29. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: A statement by the working group on endothelin and endothelial factors of the European Society of Hypertension. J Hypertens 2005;23:7-17. (Pubitemid 40128972)
30. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001;285:1711-8.
31. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
32. Spencer FA, Allegrone J, Goldberg RJ, Gore JM, Fox KA, Granger CB, Mehta RH, Brieger D. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004;140:857-66.
33. Gould KL, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994;89(4):1530-8.
34. Gould KL, Ornish D, Scherwitz L, Brown S, Edens RP, Hess MJ, Mullani N, Bolomey L, Dobbs F, Armstrong WT, Merritt T, Ports T, Sparler S, Billings J. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA 1995;274(11):894-901.